Update on development pipeline products: Botanix Pharmaceuticals Ltd (ASX: BOT), medical dermatology company, gave the update on the progress of their key development pipeline products (BTX 1801 and BTX 1308) and outlined the data and market opportunity for its new BTX 1801 antimicrobial product. The company’s newest pipeline product is BTX 1801, whose pre-clinical testing is completed, and shows that this formulation has achieved high levels of bacteria killing effect compared with cannabidiol or Permetrex alone. However, the development of new and novel antimicrobials is now the subject of a globally coordinated effort. The market opportunity for the new antimicrobials is significant and there is demand as many unmet patient needs remain. Moreover, BTX has also completed its BTX 1308 psoriasis pre-clinical formulation and testing work. This supports the mechanism of action for the drug in addressing inflammation, bacterial infection and immune system modulation. BTX is now advancing a psoriasis patient study with this data in hand, which will compare a number of BTX 1308 formulations against placebo. The company is on track to commence Phase 1b psoriasis patient study in 3Q CY2018. Meanwhile, BOT stock has fallen 33.33% in one month as on June 29, 2018.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.